Ironwood raises $50 million for IBS product development
This article was originally published in Scrip
Executive Summary
Ironwood Pharmaceuticals has raised $50 million in private equity financing primarily to support the development of linaclotide, its Phase III gastrointestinal compound. The money will fund linaclotide's development in irritable bowel syndrome with constipation (IBS-C) and chronic constipation, as well as its other candidates and commercial expansion.